Injectable Drug Delivery Evolving as Protein Drugs for Chronic Conditions Proliferate

New Survey by Greystone Associates Analyzes Development and Business Factors Driving the Demand for Injectable Drug Delivery Devices

[ClickPress, Mon Mar 12 2007] As pharmaceutical companies struggle to position their products in the direct-to-consumer marketing era, the trend toward combining functionality and packaging in drug delivery systems is growing. Innovative drug delivery systems allow pharmaceutical companies to differentiate drug products from competitors. This is essential at a time when many patents are running out and competition among the manufacturers of generic medicines is increasing.

As patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that new drug product success no longer only depends on the medication itself but also on achieving a patient-friendly form of application.

New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Reusable injectors designed to accept prefilled syringes or drug cartridges will improve ease-of-use and increase alternative device share of the growing self-injection market. Disposable prefilled models will penetrate selected practitioner segments such as wellness vaccines. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.

These findings are contained in a new and comprehensive report, Injectable Drug Delivery: Evolving Markets, Emerging Opportunities. Growth of alternative injection devices will be driven by a number of factors, including improved patient compliance and patient quality-of-care, and the trend toward drug therapy self-administration.

More information is available at www.greystoneassociates.org .

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org

Source: Greystone Associates

Bookmark this release: Del.icio.us - Digg - Furl - Blinklist - Reddit